4 Things You Need to Know About Your Medicare Advantage Plan in 2026

Medicare Advantage plans often provide supplemental benefits and an annual out-of-pocket cap that can materially affect retirees' healthcare spending, but plan-specific premiums, deductibles, copays, provider networks and eligibility rules vary and may change year-to-year. Key operational details for 2026 include that enrollees generally must continue paying Medicare Part B (though some plans cover it) and that a special Medicare Advantage enrollment period runs Jan. 1–Mar. 31, allowing switches that could influence insurer enrollment flows and provider utilization patterns.

Analysis

Market structure: Medicare Advantage growth and its annual Jan–Mar switching window concentrate pricing and utilization power with the large MA insurers (UnitedHealth UNH, Humana HUM, Elevance ELV, CVS Aetna CV S). Winners: managed-care insurers and in-network ancillary vendors (dental, hearing, home-care providers); losers: out-of-network specialists and small regional hospitals facing narrower panels and higher claims scrutiny. Narrowing networks shift margin leverage to payors, implying gradual compression of provider unit economics over 6–24 months.

Risk assessment: Key tail risks are CMS payment-rate reductions or aggressive audits/recoupments (low-probability but >$1–3B industry P&L swing), and legal/provider pushback on network terminations. Immediate (days) risk is enrollment churn through Mar 31; short-term (weeks–months) is margin visibility into Q1–Q2 2026; long-term (years) is secular MA penetration with upside demographics but regulatory volatility. Hidden dependency: risk-adjustment receipts drive ~5–10% of MA plan EBITDA and can flip profitability quickly if coding/audit rules tighten.

Trade implications: Tactical longs in UNH/HUM/ELV (2–3% position sizes each aggregate) to capture enrollment and benefit-tailwind into H1 2026; pair trade long ELV, short HCA (1.5% each) to express insurer vs. hospital pricing power. Use 3–6 month call spreads on UNH/HUM ahead of CMS rate notices and protective put spreads on HCA for downside; enter now and reprice after CMS draft/final notices (expected by April) or after Q1 earnings.

Contrarian angles: Consensus underweights ancillary and home-based care vendors that benefit if MA expands supplemental benefits — these could rerate +5–15% over 12–24 months. Conversely, market may be overpricing regulatory downside into large-cap insurers; a neutral/positive CMS rate would likely re-rate UNH/HUM +5–10% within weeks. Watch for unintended consequence: tighter networks accelerating provider M&A, which would restore some hospital pricing power longer term.

Key Decisions for Investors

• Establish 2–3% long position in UNH and 1–2% long in HUM (total initial exposure ~3–5% of portfolio) to capture MA enrollment growth; hold through Mar 31 and re-evaluate after CMS draft rate notice (expected by April).
• Implement a relative-value pair: long 1.5% ELV vs short 1.5% HCA to play insurer pricing power vs hospital reimbursement pressure; set stop-loss at 6% adverse move and take profits at 8–12% relative outperformance or after Q2 2026 results.
• Buy Apr–Jun 2026 call spreads on UNH and HUM (slightly OTM) sized to cost no more than 0.5–1.0% of portfolio each to capture upside from favorable CMS/actionable enrollment; hedge with Apr–Jun 2026 HCA put spreads (cost <0.5% portfolio) to limit tail loss.
• Reallocate 2–3% from broad hospital exposure into ancillary/home-care names (start with 1–2% positions in public hearing/dental/home-health equities such as AFN.MI/selected US home-health tech) — increase if MA supplemental utilization prints >+5% QoQ.
• Hard triggers: if CMS final MA benchmark change ≤ -2% vs prior year, reduce insurer longs by 50% within 3 trading days; if CMS holds/increases benchmarks, add 50% to insurer longs within 5 trading days.